# PrognosAI-X: Clinical Decision Support Report

## 1. CLINICAL STUDY OVERVIEW
- **Patient Identifier:** PX_101
- **Scan Modality:** Magnetic Resonance Imaging (MRI) - **FLAIR** Protocol
- **Preprocessing Sequence:** Skull Stripping, Bilateral Filtering, CLAHE Enhancement, Z-Score Normalization
- **Study Date:** June 22, 2026

---

## 2. QUANTITATIVE IMAGING ANALYSIS
The segmentation subsystem successfully localized the tumor mass. Quantitative assessment of the extracted region of interest (ROI) yielded the following morphological and texture biomarkers:
- **Tumor Area:** `1420.50 mm²`
- **Tumor Perimeter:** `182.40 mm`
- **Boundary Regularity (Circularity):** `0.54` (Value of 1.0 represents a perfect circle. A lower value indicates complex, micro-lobulated infiltrative borders).
- **Relative Intensity Density:** `1.58` (Signal ratio relative to healthy brain tissue. Values > 1.3 indicate high contrast enhancement, consistent with high cellular density or edema).
- **Texture Analysis (GLCM Contrast):** `0.88` (High contrast indicates structural heterogeneity within the lesion, often correlating with focal necrosis).
- **Texture Uniformity (GLCM Energy):** `0.12`

---

## 3. MODEL PERFORMANCE & STABILITY
Multi-stage classification and segmentation networks processed the imaging data with high operational metrics:
- **Segmentation Model:** `Attention U-Net`
  - **Dice Similarity Coefficient:** `0.895`
  - **Intersection over Union (IoU):** `0.812`
- **Classification Subsystem:** `ResNet50 + Vision Transformer Ensemble (Pipeline C)`
  - **Predicted Pathological Class:** **Tumor Detected**
  - **Model Softmax Probability:** `94.6%`

---

## 4. EXPLAINABILITY & BIOMEDICAL TRUST CHECK
Explainable AI (XAI) heatmaps (Grad-CAM, Grad-CAM++, Score-CAM, Integrated Gradients, and SHAP) were generated and compared against the segmentation mask to ensure clinical alignment:
- **Heatmap Spatial Alignment:** **Correct Focus** (IoU Overlap: `0.680`)
- **Explainability Confidence Score:** `0.838` (Integrates classification confidence and visual alignment to measure trust).
*Trust Validation:* The visual highlight maps verify that the network is focusing its parameters on the active tumor margins rather than background artifacts or skull tissue.

---

## 5. INTERPRETIVE RISK DIAGNOSIS
- **Assessed Clinical Risk Category:** **High Risk** (Risk Score: `8.5/10.0`)
- **Radiological Interpretation:** Large, highly irregular tumor boundary with micro-texture heterogeneity. Suggestive of high-grade aggressive neoplasm. The extracted biomarkers indicate a lesion of high risk profile.

---

## 6. TARGETED CLINICAL RECOMMENDATIONS
1. **Contrast Study:** Recommend a dynamic contrast-enhanced (DCE) MRI to further evaluate the vascular perfusion and blood-brain barrier permeability.
2. **Neurosurgical Consultation:** Refer to neuro-oncology board for surgical resection planning or stereotactic biopsy, as indicated by the lesion volume and boundary irregularity.
3. **Serial Surveillance:** If clinical presentation is benign, establish a baseline 3-month MRI follow-up protocol.
4. **Correlation:** Correlate with patient symptomatology (e.g. headaches, focal neurological deficits, seizures).

---

**MANDATORY CLINICAL DISCLAIMER:** *This report is generated automatically by a deep learning framework as a clinical decision-support tool. It does not replace the professional diagnosis, clinical examination, or consultation of a qualified medical practitioner, neurosurgeon, or radiologist.*
